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The effects of mastoparan on phospholipase C-catalysed phosphoinositide hydrolysis were examined in rH]inositol-la- 
belled human neuroblastoma SH-SYSY cells. PH]Inositol phosphate formation in intact cells was not altered by 20 PM 
mastoparan. In contrast, PH]inositol phosphate formation in electrically permeabilized cells stimulated with guanosine 
S-[y-thioltriphosphate and/or carbachol was inhibited by mastoparan with half-maximal effects at approx. 3 PM. The 
peptide was much less effective in inhibiting stimulatory effects of Ca2+. Similar but less potent inhibitory effects were 
observed with the cations, neomycin and spermine, indicating that direct interaction of mastoparan with polyphosphoino- 
sitides might account for its inhibitory effects on inositol phosphate formation. 
Mastoparan; Phosphoinositide hydrolysis; G-protein; Muscarinic receptor; (SH-SYSY cell) 
1. INTRODUCTION 
The peptide mastoparan (Ile-Asn-Leu-Lys-Ala- 
Leu-Ala-Ala-Leu-Ala-Lys-Lys-Ile-Leu-NHz) is a 
component of wasp (Vespula lewisii) venom that 
exhibits a range of biological activities that include 
stimulation of secretion from a variety of cell types 
[l] and activation of phosphqlipase AZ [2]. As it is 
amphiphilic, mastoparan interacts strongly with 
phospholipids and assumes an a-helical conforma- 
tion upon binding to phosphatidylcholine vesicles 
[3]. Interest in the actions of mastoparan has been 
stimulated recently by findings that the peptide 
enhances GTP-analogue binding to and GTPase 
activity of guanine nucleotide-binding regulatory 
proteins [4]. 
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Phosphoinositides including PIP2 are pivotal to 
cell function as hydrolysis of PIP2 by phospho- 
lipase C is stimulated by binding of agonists to a 
variety of receptors and leads to the formation of 
the intracellular second messengers inositol, 
1,4,5-trisphosphate and diacylglycerol [5,6]. The 
location of PIP2 within the plasma membrane and 
its importance as a precursor of second messengers 
make this phospholipid and the proteins involved 
in its hydrolysis possible and important targets for 
mastoparan. Thus, using SH-SYSY human neuro- 
blastoma cells [7] that express muscarinic receptors 
linked to phospholipase C [8,9], we have examined 
the effects of mastoparan on phosphoinositide 
hydrolysis. 
2. EXPERIMENTAL 
SH-SYSY cells were cultured in 175 cm* flasks as described 
18) and were radiolabelled by incubation of 5-day-old cultures 
for 2 days with 4&i [‘H]inositol/ml of culture medium. 
Labelled cells were mechanically removed from culture flasks, 
were washed twice in CaZ+/Mg2+-free phosphate-buffered 
saline and were finally resuspended in ice-cold ‘cytosol-like’ 
buffer (120 mM KCI, 20 mM Na Hepes, 6 mM MgC12, 2 mM 
KH2P04, 0.1 mM EGTA, 2 mM NaATP, 0.5 mg/ml bovine 
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serum albumin, pH 7.5, and pCa*+ 6.9; 1.6 ml per flask of 
cells). Aliquots (0.8 ml) of this suspension were exposed to dis- 
charges of a 3 pF capacitor (field strength, 3.75 kV/cm; time 
constant, 0.1 ms) spaced by 2 s intervals. The aliquots were then 
diluted to 2 ml and 100 ~1 portions were dispensed into ice-cold 
polypropylene tubes containing reagents to give 200 bl of a mix- 
ture composed of ‘cytosol-like’ buffer with 3 mM NazATP, 
0.75 mg/ml bovine serum albumin and appropriate stimuli. All 
experimental incubations were for 5 min at 37°C and were ter- 
minated by addition of 1 ml methanol/l M HCI (2: l), 0.1 ml 
water and 1 ml chloroform. The samples were then thoroughly 
mixed and centrifuged (1700 x g for 10 min) and 1 ml of upper 
phases were neutralized, diluted and applied to Dowex AG l-X8 
resin (200-400 mesh, formate form) and [‘Hlinositol phos- 
phates ([3H]IPs) were eluted with 3 ml of 1 .O M ammonium for- 
mate/O.1 M formic acid [lo]. Background radioactivity (that 
present in unincubated samples) was unaffected by the stimuli 
used and in all experiments was subtracted from radioactivity 
recovered after experimental incubations. All data shown are 
mean f SE of 3 independent experiments. Approx. 70000 dpm 
of [‘HIlipid per tube was present at the start of incubations. 
SH-SYSY cells were a gift from Dr J.L. Biedler, Sloan- 
Kettering Institute, USA. [3H]Inositol (D-myo-[Z3H(N)]- 
inositol, approx. 15 Ci/mmol) was obtained from NEN; 
guanosine 5’-[y-thioltriphosphate (GTP[S]) was from Boeh- 
ringer Mannheim Biochemicals; and synthetic mastoparan, car- 
bachol, neomycin, Na2ATP and spermine were from Sigma. 
3. RESULTS 
The muscarinic agonist carbachol (1 mM), the 
hydrolysis-resistant GTP analogue GTP[S] (0.1 
mM) and Ca’+ were employed as stimuli of phos- 
pholipase C activity. It was necessary to perme- 
abilize cells before stimulatory effects of Ca2+ and 
GTP[S] were apparent (not shown). Mastoparan 
(20 PM) did not affect basal (not shown) or stimu- 
lated [3H]IP levels in intact cells (fig.1) but in- 
hibited the effects of carbachol/GTP[S] after 3 or 
more discharges (fig.1). The total inhibition by 
mastoparan of the effects of carbachol/GTP[S] 
after 9 or 12 discharges (fig.1) correlates with the 
inability of cells treated in this manner to exclude 
trypan blue or to retain [3H]IPs in the intracellular 
compartment (not shown) and indicates that the 
cells have been fully permeabilized. The somewhat 
surprising increase in stimulated t3H]IP levels caus- 
ed by exposure to 3-9 discharges (fig.1) was not 
seen in parallel experiments conducted in the 
presence of Li+ (4 mM), which inhibits inositol 
phosphate phosphatases [ 11,121 and which enhanc- 
ed stimulated t3H]IP accumulation by 75% only in 
intact cells (not shown). Apparently, therefore, on- 
ly in intact cells were [3H]IPs actively dephos- 
phorylated. 
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Fig. 1. Effects of electroporation on responsiveness to 
mastoparan. [‘HlInositol-labelled cells in suspension were ex- 
posed to 0, 3, 6,9 or 12 discharges and were incubated at 37°C 
for 5 min with either no further addition (0) or with 1 mM car- 
bachol10.1 mM GTP[S] in the absence (0) or presence (m) of 
20pM mastoparan. [“H]IP formation was normalized to that 
(2910 + 290 dpm) obtained in carbachol/GTP[S]-stimulated in- 
tact cells. 
Mastoparan inhibited the stimulatory effects of 
carbachol and/or GTP[S] in permeabilized cells 
maximally by > 80% with half-maximal effects at 
approx. 3 PM, but did not alter basal [‘H]IP levels 
(fig.2). In contrast, 20 PM mastoparan inhibited 
the effects of 0.2 mM and 0.5 mM Ca2+ by only 
33% and 23%, respectively (fig.2). These effects 
reflected changes in the rate of polyphospho- 
inositide hydrolysis since PIP2 levels were reduced 
by carbachol/GTP[S] and by Ca2+, mastoparan 
(20 PM) reversed only the reduction caused by car- 
bachol/GTP[S], and the majority of [3H]IPs 
formed in stimulated cells were derived from 
polyphosphoinositide rather than phosphatidylino- 
sitol hydrolysis (not shown). The polyamine sper- 
mine and the antibiotic neomycin also inhibited 
carbachol/GTP[S]-stimulated [3H]IP formation 
(with half-maximal effects at approx. 1.5 mM and 
0.3 mM, respectively) and again were less potent 
inhibitors of the effects of Ca2+ (fig.3). 
The inhibitory effects of mastoparan were 
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F’ig.2. Dose-dependence of inhibitory effects of mastoparan. 
[3H]Inositol-labelled cells that had been exposed to 12 dis- 
charges were incubated for 5 min at 37°C with either no further 
addition (0), 0.1 mM GTP[S] ( q ), 1 mM carbachol (o), 
0.1 mM GTP[S]/l mM carbachol (m), 0.2 mM Ca*+ (A) or 
0.5 mM Ca2+ (A) and a range of mastoparan concentrations. 
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destroyed by preincubation of the peptide with 
trypsin, which will cleave the peptide at its lysine 
residues (not shown). Thus, it is the intact peptide 
that possesses the inhibitory activity. 
4. DISCUSSION 
Stimulation of [3H]IP production by GTP[S], 
the synergy between carbachol and GTP[S] when 
these agents were co-incubated, and additional 
studies in permeabilized SH-SYSY cells on the 
specificity of nucleotide effects on [3H]IP produc- 
tion [13] indicate that a G-protein, that has been 
termed Gp [14,15], is involved in coupling the 
muscarinic receptors of SY-SYSY cells to increased 
polyphosphoinositide hydrolysis. 
In contrast to findings that mastoparan tran- 
siently stimulates PIP2 hydrolysis and IP forma- 
tion in intact mast cells [ 161, the peptide did not af- 
fect polyphosphoinositide hydrolysis in intact SH- 
SYSY cells and was inhibitory if it had access to the 
cell interior, Two lines of evidence indicate that the 
intracellular site with which mastoparan interacts 
might be PIP2 and that such an interaction inhibits 
PIP2 hydrolysis. Firstly, mastoparan interacts with 
phospholipids [1,3] and because it contains 3 
5ooo I 
[ NEOMYCIN J ( log &I ) 
Fig.3. Dose-dependence of inhibitory effects of spermine and neomycin. [3H]Inositol-labelled cells that had been exposed to 12 
discharges were incubated as in fig.2 with a range of spermine or neomycin concentrations. 
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positively charged lysine residues at neutral pH it 
should interact particularly strongly with a poly- 
anion like PIP2. Secondly, the cations spermine 
and neomycin both inhibit the effects of car- 
bachol/GTP[S] in permeabilized cells. Both com- 
pounds bind to PIP2 [17,18] and inhibit phospho- 
lipase C-catalysed PIP2 hydrolysis [ 19,201. Apart 
from the greater potency of mastoparan, the in- 
hibitory characteristics of mastoparan, neomycin 
and spermine were similar indicating that they may 
share a common mechanism of action. Competi- 
tion between binding of these cations and Ca2+ to 
PIP2 [17,18,20] may explain the relatively low 
potency of inhibition by mastoparan, neomycin 
and spermine of Ca2+ -stimulated [3H]IP forma- 
tion. Finally, an action of mastoparan akin to the 
activating effect of the peptide on purified G- 
proteins reconstituted in phospholipid vesicles [4] 
is unlikely to subserve the inhibitory effects of the 
peptide in permeabilized SH-SYSY cells, since if 
Gp was similarly activated by mastoparan then an 
increase in [3H]IP formation would be expected. 
It is interesting to note that mastoparan mimics 
some of the effects of G-protein &subunits. Both 
,8y and mastoparan stimulate phospholipase AZ ac- 
tivity [21,2] and inhibit phospholipase C activity 
([22] and this study). Thus, these agents may share 
a common mechanism of action that is perhaps 
related to the ability of both mastoparan [1,3] and 
fly [23] to interact strongly with phospholipid 
membranes. 
In conclusion, mastoparan is a potent inhibitor 
of phospholipase C activity in permeabilized cells. 
While this may not be relevant to its biological 
function [l], mastoparan appears to interfere with 
the sequence of events initiated by receptor and/or 
Gp activation that lead to increased PIP2 hydro- 
lysis and may, therefore, serve as a valuable tool in 
investigations of this signal transduction system. 
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